SNGX - Soligenix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.0900
+0.0400 (+1.95%)
At close: 4:00PM EST

2.1200 +0.03 (1.44%)
Pre-Market: 9:02AM EST

Stock chart is not supported by your current browser
Previous Close2.0500
Open2.1000
Bid0.0000 x 900
Ask0.0000 x 1400
Day's Range2.0800 - 2.2700
52 Week Range0.6500 - 2.2700
Volume857,767
Avg. Volume174,767
Market Cap43.165M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.5160
Earnings DateMar 23, 2020 - Mar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • Newsfile

    Soligenix Shares Power Higher Ahead of SGX301 Phase 3 Data Release; Projected $200 Million Revenue Opportunity For CTCL Drug

    Soulstring Media spots a substantial value opportunity in Soligenix, Inc.; Two near-term Phase 3 data releases can seize upon a $400 million drug market opportunity Miami Beach, Florida--(Newsfile Corp. - January 16, 2020) - Soligenix (NASDAQ: SNGX), a late-stage pharmaceutical company working to improve the current standard of care for numerous rare diseases through the development and commercialization of novel treatments, is nearing the release of topline data after completing final enrollment for SGX301, a ...

  • Zacks Small Cap Research

    SNGX: Interview with Dr. Straube Regarding the Upcoming Phase 3 CTCL Data Readout…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interview with Dr. Richard Straube Regarding Upcoming Phase 3 Data for SGX301 in CTCL Soligenix, Inc. (NASDAQ:SNGX) recently announced the completion of enrollment in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin)

  • How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid?
    Simply Wall St.

    How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid?

    Christopher Schaber became the CEO of Soligenix, Inc. (NASDAQ:SNGX) in 2006. First, this article will compare CEO...

  • PR Newswire

    Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. As a result, the Company anticipates being able to transfer this credit and receive approximately $850,000 in net proceeds.

  • Newsfile

    CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare diseases and/or areas of unmet medical need are currently in Phase 3 studies. Additionally, the Public Health Solutions arm has ...

  • PR Newswire

    Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened the study titled "A Phase 1C, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety of RiVax®, a Lyophilized Ricin Toxin A-Chain Subunit Vaccine with Alum-Adjuvant, in Healthy, Normal Adults." Preliminary safety results from the trial are expected in the second quarter of 2020 with longer-term safety and immunogenicity results from throughout the 6-month follow-up period expected in the fourth quarter of 2020.

  • Newsfile

    Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare diseases and/or areas of unmet medical need are currently in Phase 3 studies. Additionally, the Public Health Solutions arm has grown to operate under a multi-million-dollar contract with the National ...

  • SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…
    Zacks Small Cap Research

    SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 Trial of SGX301 in CTCL Fully Enrolled; Data in 1Q20 On December 3, 2019, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment has completed in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin) trial is a

  • PR Newswire

    Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The study successfully enrolled 169 subjects, following positive interim analysis, which included a prospectively defined, unblinded assessment of the study's primary efficacy endpoint by an independent Data Monitoring Committee (DMC). With enrollment completed, top-line results are expected in the first quarter of 2020.

  • PR Newswire

    Soligenix to Present at the PCG Spotlight Series Conference

    PRINCETON, N.J., Nov. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the PCG Spotlight Series Conference taking place on Thursday, November 21, 2019 at the Harvard Club, 35 West 44th Street, NYC at 2:30 pm EST. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix will be delivering the corporate presentation and reviewing upcoming milestones for the Company's two pivotal Phase 3 clinical programs.

  • If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today
    Simply Wall St.

    If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today

    Soligenix, Inc. (NASDAQ:SNGX) shareholders should be happy to see the share price up 12% in the last month. But will...

  • SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters…
    Zacks Small Cap Research

    SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Two Phase 3 Data Readouts in 2020 Soligenix, Inc. (NASDAQ:SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. The company has a number of important near-term catalysts that we believe should be on investor’s radars, including: • 1Q2020 – topline

  • PR Newswire

    Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

    PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2019. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are now approaching data read-out in two Phase 3 clinical programs. Following the recent positive recommendation received from the independent Data Monitoring Committee (DMC), we continue to enroll patients in our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer (HNC) receiving chemoradiation therapy.

  • PR Newswire

    Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference

    PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Daniel P. Ring, Vice President of Business Development and Strategic Planning, will deliver a corporate presentation reviewing the Company's two Phase 3 clinical programs and pipeline at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, Tuesday, November 12, 2019 at 10:45 AM GMT. The event will take place at Hamburg Messe, Level 1, Hall B1, room 7.

  • PR Newswire

    Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition

    Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Oct. 24, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

  • Newsfile

    Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape

    Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer Soligenix investors a near-term opportunity to enjoy the rewards of both an FDA approval and the subsequent commercial launch of at least two promising drugs, SGX301 and SGX942, each targeting ...

  • Newsfile

    Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer

    Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches, investors may be looking for any clue they can get as to how the drug is performing. That clue, incidentally, may have been provided by ...

  • PR Newswire

    Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada

    PRINCETON, N.J., Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation to review the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the Global Chinese Financial Forum (GCFF) Conference on Saturday, October 5, 2019 at 11:55 am Pacific Time. The event will take place at Vancouver Executive Hotel, Vancouver, BC, Canada.

  • PR Newswire

    Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning

    Industry veteran brings extensive experience leading business development PRINCETON, N.J. , Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

  • PR Newswire

    Soligenix Appoints Jonathan Guarino as Chief Financial Officer

    PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Jonathan Guarino, as its Senior Vice President and Chief Financial Officer.  Mr. Guarino has over 20 years of diverse experience in the financial and strategic management of emerging growth and commercial companies, including in the life sciences industry.

  • PR Newswire

    Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

    PRINCETON, N.J., Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation to review upcoming potential milestones for the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the RHK Capital 2019 Disruptive Growth Conference on Wednesday, September 4, 2019 at 9:20 AM EDT. The event will take place at 599 Lexington Avenue, 22nd floor, New York City.

  • Zacks Small Cap Research

    SNGX: Q&A on SGX942 Phase 3 Trial Interim Analysis…

    On August 28, 2019, Soligenix, Inc. (SNGX) announced a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrollment in the ongoing Phase 3 clinical trial of SGX942 in the treatment of oral mucositis in patients with head and neck cancer. The DMC recommended that approximately 70 additional subjects be randomized into the trial to maintain the 90% statistical power for the primary outcome, which will increase the study sample size from 190 to 260 subjects. The increase in study sample size was required to account for any potential variability observed in the Phase 3 trial that differs from the trials original design assumptions.

  • Benzinga

    The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines ...

  • PR Newswire

    Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

    Final topline results remain on target for first half 2020 PRINCETON, N.J. , Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company ...